Valuation: Bonesupport Holding AB

Market Cap 14.88B 1.49B 1.31B 1.24B 1.13B 2.12B 143B 2.13B 5.75B 73.19B 5.61B 5.49B 235B P/E 2026 *
46.3x
P/E 2027 * 29.5x
Enterprise Value 14.34B 1.44B 1.27B 1.2B 1.09B 2.04B 138B 2.05B 5.54B 70.52B 5.4B 5.29B 227B EV / Sales 2026 *
9.6x
EV / Sales 2027 * 7.1x
Free-Float
89.54%
Yield 2026 *
0.64%
Yield 2027 * 0.95%
1 day+5.88%
1 week+5.88%
Current month-3.24%
1 month-6.96%
3 months+10.96%
6 months+16.56%
Current year+14.83%
1 week 21.47
Extreme 21.468
22.73
1 month 21.47
Extreme 21.468
24.43
Current year 19
Extreme 19
28.57
1 year 18.57
Extreme 18.57
29.66
3 years 15.74
Extreme 15.74
35
5 years 3.83
Extreme 3.83
35
10 years 3.83
Extreme 3.83
35
Manager TitleAgeSince
Chief Executive Officer 49 01/09/2025
Director of Finance/CFO 63 01/11/2018
Chief Operating Officer 51 01/12/2021
Director TitleAgeSince
Director/Board Member 68 01/01/2010
Chairman 70 15/12/2016
Chairman 71 14/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+5.88% - - 1.49B
+0.37%+8.68%+683.32%+92.10% 78.76B
-0.91%-7.32%+32.86%-9.47% 75.12B
+0.21%+2.24%-6.14%-27.67% 61.14B
-2.26%-2.67%-8.70%+167.99% 46.07B
-1.07%-1.21%-9.92%+32.27% 47.57B
-1.31%+0.35%+63.26%-12.01% 33.79B
-2.05%-3.59%+45.88%+111.83% 25.3B
-0.26%-6.35%+2.84%+140.35% 21.34B
-0.80%-2.77%+55.98%+95.08% 15.36B
Average -0.22%+0.76%+95.49%+65.61% 44.94B
Weighted average by Cap. -0.71%+1.87%+146.52%+51.93%

Financials

2026 *2027 *
Net sales 1.49B 150M 132M 125M 113M 212M 14.39B 214M 577M 7.34B 563M 551M 23.6B 1.98B 198M 175M 165M 150M 281M 19.05B 283M 763M 9.72B 745M 729M 31.24B
Net income 319M 32.01M 28.15M 26.62M 24.15M 45.35M 3.07B 45.61M 123M 1.57B 120M 118M 5.04B 504M 50.58M 44.48M 42.06M 38.15M 71.65M 4.86B 72.07M 195M 2.48B 190M 186M 7.96B
Net Debt -543M -54.53M -47.96M -45.35M -41.14M -77.25M -5.23B -77.7M -210M -2.67B -205M -200M -8.58B -856M -85.93M -75.57M -71.46M -64.82M -122M -8.25B -122M -330M -4.21B -323M -316M -13.53B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
171
Date Price Change Volume
29/09/26 $22.73 +5.88% 500
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
227.20SEK
Average target price
356.58SEK
Spread / Average Target
+56.95%

Quarterly revenue - Rate of surprise